Dose–Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure

Abstract

Ritonavir, a potent inhibitor of cytochrome P450 isoform 3A (CYP3A) activity, is frequently used to boost the effects of protease inhibitors at doses of 100-400 mg per day; however, human data regarding the optimal dose required for boosting are limited. This study systematically evaluated the ritonavir dose-response relationship on presystemic and systemic CYP3A metabolism using the human immunodeficiency virus integrase inhibitor elvitegravir and midazolam as probe substrates. Ritonavir administered once daily with elvitegravir exhibited nonlinear pharmacokinetics, with a 119-fold increase in the area under the plasma concentration-time curve over the dosing interval over a 20- to 200-mg dose range. The 20-mg dose of ritonavir substantially reduced CYP3A-mediated clearance (CL), as evidenced by a 66% reduction in midazolam CL that plateaued to 17% of baseline activity at a 100-mg dose. Maximum inhibition of elvitegravir apparent oral CL was achieved with ritonavir doses of 50-100 mg. Elvitegravir and ritonavir were generally well tolerated in this study. These data provide a critical understanding of ritonavir's dose-response relationship for inhibition of CYP3A activity in humans.

Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors

“…treatment (24); the pharmacokinetic variability could be also due to interpatient variability in CYP3A expression levels. Mathias et al showed a doseresponse relationship of ritonavir for inhibition of CYP3A activity and elvitegravir oral exposure in humans (25). Maximum inhibition of elvitegravir apparent oral clearance was achieved with ritonavir doses of 50 to 100 mg.…”

Sex Differences of Drug-metabolizing Enzyme: Female Predominant Expression of Human and Mouse Cytochrome P450 3A Isoforms

“…Thus, ritonavir-mediated "boosting" of protease inhibitor-containing regimens has become a standard of care for nonpregnant adults. 47) Kosel and coworkers found that the induction of CYP3A4 during pregnancy was offset by this regimen, implying the usefulness of this prescription for pregnant women. 48) …”

Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines

“…30 In contrast, the investigational integrase inhibitor elvitegravir, which is in late-stage development, is a CYP3A4 substrate and requires boosting with an inhibitor to achieve therapeutic concentrations. 31 Pharmacodynamic interactions may affect the efficacy or toxicity of a drug in an additive, synergistic, or antagonistic manner. An example of an undesirable HIV-related pharmacodynamic drug-drug interaction occurs with the combination of didanosine and tenofovir.…”